Circ_0004585 Facilitates Tumorigenesis of Colorectal Cancer Modulating the MiR-338-3p/ZFX Axis and Activating the MEK/ERK Pathway
Overview
Authors
Affiliations
Background: Colorectal cancer (CRC) is a common malignant tumor in the digestive tract. Circular RNAs (circRNAs) have been identified as crucial regulators of tumorigenesis. However, the role and potential mechanism of circ_0004585 in CRC are poorly understood.
Methods: The expression of circ_0004585, microRNA-338-3p (miR-338-3p), and zinc finger protein X-linked (ZFX) was detected by quantitative real-time PCR and Western blot. Cell proliferation, cell cycle arrest, apoptosis, and angiogenesis were evaluated by 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT), 5-Ethynyl-2'-deoxyuridine (EdU), flow cytometry and tube formation assays. Western blot assay was applied to detect the expression of epithelial-mesenchymal transition (EMT)-related proteins and MEK/ERK signaling pathway-related proteins. A xenograft model was used to analyze tumor growth . The targeted relationship between miR-338-3p and circ_0004585/ZFX was verified by a dual-luciferase reporter assay.
Results: Circ_0004585 and ZFX were up-regulated, while miR-338-3p was down-regulated in CRC tissues and cells. Silencing of circ_0004585 inhibited proliferation, angiogenesis, and EMT and triggered apoptosis in CRC cells. Consistently, circ_0004585 depletion blocked tumor growth . Circ_0004585 contributed to CRC cell development sequestering miR-338-3p. Also, miR-338-3p hindered the malignant progression of CRC cells by targeting ZFX. Circ_0004585 activated MEK/ERK pathway regulating ZFX.
Conclusion: Circ_0004585 facilitated CRC progression through modulating miR-338-3p/ZFX/MEK/ERK pathway, which might provide a potential therapeutic target for CRC.
Supplementary Information: The online version contains supplementary material available at 10.1007/s12195-022-00756-6.
Taha S, Karimi M, Mahdavi B, Yousefi Tehrani M, Bemani A, Kabirian S Epigenetics Chromatin. 2025; 18(1):3.
PMID: 39810224 PMC: 11734566. DOI: 10.1186/s13072-024-00560-8.
Shahpari M, Hashemi M, Younesirad T, Hasanzadeh A, Mosanne M, Ahmadifard M Heliyon. 2024; 10(21):e37089.
PMID: 39524849 PMC: 11546195. DOI: 10.1016/j.heliyon.2024.e37089.
Mao J, Lu Y Cancer Gene Ther. 2024; 31(6):831-841.
PMID: 38337038 DOI: 10.1038/s41417-024-00739-x.